IMMUNITYBIO INC

ImmunityBio insider trades show a disciplined buying‑and‑selling pattern, revealing investor confidence and the company’s strong growth prospects.

Insider sale of 25k ImmunityBio shares under Rule 10b‑5 shows tactical timing amid a 20% weekly rally and 535% buzz spike—watch for future clinical data.

Insider buying at ImmunityBio signals executive confidence ahead of the ANKTIVA FDA review—potential upside for the $7.25B biotech stock.

Insider selling at ImmunityBio drops shares by 23k – investors learn it’s a liquidity move, not a warning, while the biotech’s pipeline keeps value upside.

Investor insights: Simon Barry J’s recent insider sell‑offs on ImmunityBio stock are routine portfolio moves, not a red flag for the company’s growing oncology pipeline and strong financials.

Insider buying shows confidence in ImmunityBio’s growth—executives buy low, sell high and exercise options amid Anktiva sales and new approvals.

Insider trading at ImmunityBio shows Patrick Soon‑Shiong buying RSUs then selling shares, hinting at short‑term liquidity moves amid an upcoming ASCO data release.

Insider buying spree at ImmunityBio signals confidence ahead of ASCO symposium – CFO & CEO net gains hint at future upside, while RSU sales show cash‑management strategy.

Simon Barry J. sells 151,967 ImmunityBio shares via a Rule 10b5‑1 plan—insider liquidity, not loss of confidence, amid a 203% rally and strong oncology pipeline.